You are here: Home » 2023 » April » Archives for 19th

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages adidas AG Investors to Inquire About Securities Class Action Investigation – ADDYY, ADDDF

NEW YORK, April 19, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of adidas AG (OTC: ADDYY, ADDDF) resulting from allegations that adidas may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased adidas securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit–form/?case_id=12204 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

WHAT IS THIS ABOUT: On October 25, 2022, adidas ended its lucrative business partnership with Kanye West (under which it sold products designed by West under the brand name "Yeezy") as a result of his anti–Semitic rhetoric.

On November 27, 2022, The Wall Street Journal published an article entitled "Adidas Top Executives Discussed Risk of Staff's "Direct Exposure' to Kanye West Years Ago." According to the article, as early as 2018, adidas executives discussed ending the business partnership with West as a result of his behavior. Reportedly adidas feared continuing the relationship with West, as they feared it could "blow up" at any moment. The article added that West made anti–Semitic statements in front of adidas staff, and that he told adidas staff that he was considering naming an album after Adolf Hitler.

On February 9, 2023 adidas announced that "while the company continues to review future options for the utilization of its Yeezy inventory, this guidance already accounts for the significant adverse impact from not selling the existing stock. This would lower revenues by around 1.2 billion and operating profit by around 500 million this year." Further, "should the company irrevocably decide not to repurpose any of the existing Yeezy product going forward, this would result in the write–off of the existing Yeezy inventory and would lower the company's operating profit by an additional 500 million this year. In addition, adidas expects one–off costs of up to 200 million in 2023. These costs are part of a strategic review the company is currently conducting aimed at reigniting profitable growth as of 2024. If all these effects were to materialize, the company would expect to report an operating loss of 700 million in 2023." adidas' CEO stated, "[t]he numbers speak for themselves. We are currently not performing the way we should[.]"

As a result of these adverse disclosures the price of adidas securities have fallen, damaging investors.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8811744)

GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Luminar Technologies, Inc. Investors to Inquire About Securities Class Action Investigation – LAZR

NEW YORK, April 19, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Luminar Technologies, Inc. (NASDAQ: LAZR) resulting from allegations that Luminar may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Luminar securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit–form/?case_id=14243 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

WHAT IS THIS ABOUT: On or around March 17, 2023, various media outlets reported that Lidwave, an Israeli start–up, had accused Luminar of attempting to pass off a Lidwave chip as Luminar's own technology after Luminar displayed an image of the processor at a recent investor conference, as well as in materials on its website. As a result, Lidwave threatened Luminar with legal action. Luminar subsequently removed the images in question from its investor presentation, website, and a YouTube video.

On this news, Luminar's stock price fell $0.68 per share, or 8%, to close at $7.80 per share on March 20, 2023, the next trading day.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8811639)

Les généticiens de la reproduction réunis à Paris présentent le tout premier test de séquençage du génome entier dans des embryons

  • Le Dr Santiago Munn, un pionnier du diagnostic gntique primplantatoire, a prsent le nouveau test lors de la Confrence PGDIS
  • Non seulement ce nouveau test de laboratoire dtectera les gnes hrits des parents, mais il rvlera galement les nouvelles mutations pouvant mener des maladies de novo comme l'autisme

PARIS, 20 avr. 2023 (GLOBE NEWSWIRE) — Le Dr Santiago Munn, pionnier du diagnostic gntique primplantatoire, a prsent le premier test de squenage du gnome entier sur des embryons devant les participants la 20e Confrence de la Socit internationale de diagnostic gntique primplantatoire (PGDIS pour Preimplantation Genetic Diagnosis International Society), organise cette semaine Paris.

Lors de son allocution plnire laquelle ont assist plus de 300 experts, le Dr Munn, un prcurseur de la gntique de la reproduction de renomme internationale, a prsent des donnes de validation pour GenomeScreen, le test dvelopp par l'quipe de recherche qu'il dirige dans la socit de biotechnologie GenEmbryomics.

Nous savions, depuis que nous avons commenc travailler sur le diagnostic embryonnaire en 1993, que la slection embryonnaire serait dterminante pour la grossesse, surtout chez les patientes plus ges. Au cours des 30 dernires annes, notre travail s'est concentr sur l'amlioration de la slection embryonnaire gntique, mme si l'approche diagnostique dfinitive (celle qui fournit le plus d'informations et les meilleurs rsultats) sera sans aucun doute celle–ci : le squenage du gnome entier de l'embryon l'aide de quelques cellules seulement obtenues partir d'une biopsie. Ce test va ouvrir des portes dont nous ignorions jusqu' l'existence , a dclar le Dr Munn sur le travail accompli chez GenEmbryomics.

Comprendre le gnome, cela signifie tout savoir sur un embryon avant le transfert
GenomeScreen est un nouveau test rvolutionnaire sur le squenage du gnome entier pour les embryons issus de FIV, qui a t dcrit par les autorits comme le test gntique le plus complet dans la FIV lors du forum PGDIS.

Le test apporte des renseignements extrmement prcis sur la squence du gnome de l'embryon et sur les parents gntiques, fournissant aux familles des informations primplantatoires dterminantes sur la sant de l'embryon et le pronostic de reproduction pouvant clairer leurs dcisions. Par ailleurs, ces informations seront inestimables pour les personnes nes d'une FIV, car elles fourniront des donnes sur la nutrignomique ou des conseils sur les mdicaments les plus gntiquement adapts au/ la patient(e).

Au tout dbut de nos recherches sur le squenage d'embryons, notre objectif tait de crer un outil complet et puissant, qui pourrait doter les mdecins de la fertilit de donnes exhaustives pour des dpistages de prcision , s'est souvenu le Dr Nick Murphy, fondateur de GenEmbryomics. Maintenant que nous avons cet outil et que nous l'utilisons avec une fiabilit de 99 %, nous avons conscience que ce diagnostic nous fournit des informations, mais amliore galement considrablement le succs de la mdecine de reproduction , a ajout le Dr Murphy.

Le squenage des embryons va augmenter les taux de russite des FIV

Le professeur Munn, dont la carrire en tant que chef de file en gntique reproductive s'tend sur plus de 20 ans, a apport d'normes contributions la slection embryonnaire et au traitement de FIV. Avec ce test, lui et son quipe de chercheurs solidifient le rle des tests gntiques dans la mdecine de reproduction, augmentant le succs des traitements.

Selon le professeur Munn : Les conclusions prsentes lors de la confrence constituent les donnes de validation d'un test qui va changer la slection embryonnaire telle que nous la connaissons . L'analyse gntique primplantatoire avec squenage du gnome entier reprsente un pas de gant : entre autres choses, elle nous dira quels embryons s'implanteront avec succs, car nous saurons l'avance lesquels sont vraiment en bonne sant, c'est––dire sans maladie hrite des parents ou sans maladie de novo, comme l'autisme , a–t–il conclu.

propos de GenEmbryomics
Fonde par le Dr Nick Murphy en 2019, GenEmbryomics est une socit de biotechnologie de pointe spcialise dans l'analyse gnomique des embryons afin de dterminer les candidats les plus viables pour une implantation par FIV. Son travail conduira des taux de russite plus levs dans les cycles de FIV, grce ses algorithmes propritaires qui permettent une slection embryonnaire plus prcise et plus efficace, base sur le gnome entier de chaque embryon.


GLOBENEWSWIRE (Distribution ID 8811736)

Geneticistas Reprodutivos Reunidos em Paris Apresentam Primeiro Teste de Sequenciamento Completo do Genoma Embriões

  • Dr. Santiago Munn, pioneiro no diagnstico gentico pr–implantao, apresentou o novo teste na Conferncia PGDIS
  • Alm de detectar genes herdados dos pais, o novo teste de laboratrio tambm revela novas mutaes que podem levar a doenas "de novo", como o autismo.

PARIS, April 19, 2023 (GLOBE NEWSWIRE) — O Dr. Santiago Munn, pioneiro no diagnstico gentico pr–implantao, apresentou o primeiro teste de sequenciamento completo do genoma em embries para representantes na Preimplantation Genetic Diagnosis International Society (20 Conferncia da Sociedade Internacional de Diagnstico Gentico Pr–implantao – PGDIS), realizada esta semana em Paris.

Em seu discurso no plenrio com a presena de mais de 300 especialistas, o Dr. Munn, pioneiro em gentica reprodutiva internacionalmente reconhecido, apresentou dados de validao do GenomeScreen, teste desenvolvido pela equipe de pesquisa liderada por ele na empresa de biotecnologia GenEmbryomics.

"Sabemos desde que comeamos a trabalhar com o diagnstico de embries em 1993 que a seleo de embries seria fundamental para a gravidez, especialmente em pacientes mais velhas. Nos ltimos 30 anos, nosso trabalho tem se concentrado em aprimorar a seleo gentica de embries, embora a abordagem diagnstica definitiva – que fornece mais informaes e melhores resultados – seja, sem dvida, esta: sequenciamento completo do genoma do embrio usando apenas algumas clulas obtidas de uma bipsia. Este teste abre portas que no sabamos que existiam", disse Munn sobre o trabalho realizado na GenEmbryomics.

Conhecer o genoma conhecer um embrio antes da transferncia
O GenomeScreen um novo e revolucionrio teste de sequenciamento completo do genoma para embries de fertilizao in vitro descrito como "o teste gentico mais completo de fertilizao in vitro" pelas autoridades do frum PGDIS.

O teste fornece informaes altamente precisas sobre a sequncia do genoma do embrio e dos pais genticos, oferecendo s famlias os principais insights pr–implantao sobre a sade do embrio e o prognstico reprodutivo para a tomada decises bem–informadas. Alm disso, essas informaes so inestimveis para pessoas geradas de fertilizao in vitro, pois fornecem informaes sobre nutrigenmica ou orientao sobre quais medicamentos so mais geneticamente adequados para o paciente.

"Quando comeamos nossa pesquisa sobre o sequenciamento de embries, nosso objetivo era criar uma ferramenta potente e abrangente para que os mdicos de fertilidade pudessem acessar dados completos para uma avaliao precisa", disse o Dr. Nick Murphy, fundador da GenEmbryomics. "Com essa ferramenta usada com 99% de confiabilidade, sabemos que, alm de fornecer informaes, esse diagnstico tambm aumenta substancialmente o sucesso da medicina reprodutiva", acrescentou Murphy.

O sequenciamento de embries aumenta o ndice de sucesso da fertilizao in vitro

O professor Munn, lder em gentica reprodutiva de mais de 20 anos, um importante contribuinte para seleo de embries e o tratamento de fertilizao in vitro. Com este teste, ele e sua equipe de pesquisadores solidificam o papel dos testes genticos na medicina reprodutiva, aumentando o sucesso do tratamento.

"Os resultados apresentados na conferncia so os dados de validao de um teste que ir alterar a forma como a seleo de embries realizada", disse Munn. "A anlise gentica pr–implantao com sequenciamento completo de genoma um passo gigantesco: entre outras coisas, informar qual embrio ser implantado com sucesso, porque saberemos de antemo qual deles verdadeiramente saudvel – sem doenas herdadas dos pais ou doenas de novo, como o autismo", conclui ele.

Sobre a GenEmbryomics
Fundada pelo Dr. Nick Murphy em 2019, a GenEmbryomics uma empresa de biotecnologia de ponta especializada na anlise genmica de embries para determinar os candidatos mais viveis para a implantao de fertilizao in vitro. Seu trabalho proporcionar ndices de maior sucesso nos ciclos de fertilizao in vitro, graas aos seus algoritmos proprietrios que oferecem uma seleo de embries mais precisa e eficiente, com base em todo o genoma de cada embrio.


GLOBENEWSWIRE (Distribution ID 8811736)

In Paris versammelte Reproduktionsgenetiker präsentieren den ersten Test zur Gesamtgenomsequenzierung bei Embryonen

  • Dr. Santiago Munn, ein Pionier auf dem Gebiet der genetischen Primplantationsdiagnostik, stellte den neuen Test auf der PGDIS–Konferenz vor
  • Der neuartige Labortest wird nicht nur die von den Eltern vererbten Gene nachweisen, sondern auch neue Mutationen aufdecken, die zu De–novo–Erkrankungen wie Autismus fhren knnten

PARIS, April 20, 2023 (GLOBE NEWSWIRE) — Dr. Santiago Munn, ein Pionier auf dem Gebiet der Primplantationsdiagnostik, prsentierte den Delegierten der 20. Konferenz der Preimplantation Genetic Diagnosis International Society (PGDIS), die diese Woche in Paris stattfand, den ersten Test zur Gesamtgenomsequenzierung bei Embryonen.

In seinem Plenarvortrag, an dem ber 300 Experten teilnahmen, stellte Dr. Munn, ein international anerkannter Wegbereiter der Reproduktionsgenetik, Validierungsdaten fr den Test GenomeScreen vor, der von dem von ihm geleiteten Forschungsteam des Biotechnologieunternehmens GenEmbryomics entwickelt wurde.

"Seit wir 1993 mit der Primplantationsdiagnostik begonnen haben, wissen wir, dass die Embryonenselektion der Schlssel zu einer Schwangerschaft ist, insbesondere bei lteren Patientinnen. In den letzten 30 Jahren hat sich unsere Arbeit auf die Verbesserung der genetischen Embryonenselektion konzentriert, obwohl der definitive diagnostische Ansatz "" derjenige, der die meisten Informationen und die besten Ergebnisse liefert "" zweifellos dieser sein wird: die Gesamtgenomsequenzierung bei Embryos anhand einiger weniger anhand einer Biopsie gewonnenen Zellen. Dieser Test wird Tren ffnen, von denen wir nicht wussten, dass sie existieren", sagte Munn ber die Arbeit bei GenEmbryomics.

Das Genom zu verstehen bedeutet, vor der Implantation alles ber einen Embryo zu wissen GenomeScreen ist ein revolutionrer neuer Test zur Gesamtgenomsequenzierung von IVF–Embryonen, der von den Experten auf dem PGDIS–Forum als "der umfassendste genetische Test in Bezug auf IVF" bezeichnet wurde.

Der Test liefert hochprzise Informationen ber die Genomsequenz des Embryos und der genetischen Eltern und bietet den Familien vor der Implantation wichtige Erkenntnisse ber die Gesundheit des Embryos und die Fortpflanzungsprognose, die fr deren Entscheidungen hilfreich sein knnen. Zudem sind diese Informationen von unschtzbarem Wert fr Menschen, die mithilfe der IVF geboren wurden, da sie einen Beitrag zur Nutrigenomik leisten oder Hinweise darauf geben, welche Medikamente fr den Patienten genetisch am besten geeignet sind.

"Als wir mit unseren Forschungen zur Sequenzierung von Embryonen begannen, war es unser Ziel, ein leistungsfhiges, umfassendes Instrument zu schaffen, das Fruchtbarkeitsrzten umfassende Daten fr ein przises Screening liefern kann", erinnert sich Dr. Nick Murphy, Grnder von GenEmbryomics. "Jetzt, da wir ber dieses Instrument verfgen und es mit einer Zuverlssigkeit von 99 % einsetzen, wissen wir, dass diese Diagnose nicht nur Informationen liefert, sondern auch den Erfolg der Reproduktionsmedizin erheblich steigert", fgte Murphy an.

Sequenzierung von Embryonen wird die IVF–Erfolgsraten erhhen

Professor Munn, der seit ber 20 Jahren auf dem Gebiet der Reproduktionsgenetik fhrend ist, hat enorme Beitrge zur Selektion von Embryonen und zur IVF–Behandlung geleistet. Mit diesem Test festigen er und sein Forscherteam die Rolle der Gentests in der Reproduktionsmedizin und erhhen den Behandlungserfolg.

"Die auf der Konferenz vorgestellten Ergebnisse sind die Validierungsdaten fr einen Test, der die Embryonenselektion, wie wir sie kennen, verndern wird", so Munn. "Die genetische Primplantationsanalyse anhand der Gesamtgenomsequenzierung ist ein groer Schritt nach vorn: Sie wird uns unter anderem Aufschluss darber geben, welcher Embryo sich erfolgreich einnisten wird, weil wir vorher wissen, welcher Embryo wirklich gesund ist, d. h. frei von Krankheiten, die von den Eltern vererbt wurden, oder von De–novo–Erkrankungen wie Autismus", schloss er.

ber GenEmbryomics
GenEmbryomics wurde 2019 von Dr. Nick Murphy gegrndet und ist ein innovatives Biotechnologieunternehmen, das sich auf die Genomanalyse von Embryonen spezialisiert hat, um die lebensfhigsten Kandidaten fr eine IVF–Implantation zu ermitteln. Die Arbeit des Unternehmens wird zu hheren Erfolgsquoten bei IVF–Zyklen fhren, da seine firmeneigenen Algorithmen eine genauere und effizientere Embryonenauswahl auf der Grundlage des gesamten Genoms eines jeden Embryos ermglichen.


GLOBENEWSWIRE (Distribution ID 8811736)

ROSEN, A LEADING LAW FIRM, Encourages Fox Corporation Investors to Inquire About Class Action Investigation – FOX, FOXA

NEW YORK, April 19, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Fox Corporation (NASDAQ: FOX, FOXA) resulting from allegations that FOX may have issued materially misleading business information to the investing public. The prospective class includes those who purchased FOX call options and/or sold put options.

SO WHAT: If you purchased FOX securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit–form/?case_id=13327 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

WHAT IS THIS ABOUT: In the wake of the 2020 U.S. Presidential Election, Dominion Voting Systems sued FOX for defamation. Dominion's lawsuit alleges that FOX defamed Dominion's business by endorsing, repeating or broadcasting a series of "verifiably false yet devastating lies about Dominion." Dominion claims that various statements that were made on FOX News, including that Dominion committed election fraud by rigging the 2020 election, that Dominion's software and algorithms manipulated vote counts in the 2020 election, that Dominion was founded for the purpose of rigging elections, and that Dominion paid kickbacks to government officials who used its machines, were defamatory and false. Dominion seeks over $1.6 billion in damages, as well as additional punitive damages.

Beginning in February 2023, specific details emerged of internal discussions at FOX in the wake of the 2020 election, revealing that FOX's senior leaders understood that claims to the effect that Dominion had rigged the 2020 election were false. As a consequence, FOX faces significant potential legal liability.

As a result of ongoing revelations about FOX's legal exposure in the Dominion lawsuit, FOX's Class A stock has declined from a closing price of $37.03 on February 17, 2023 to a closing price of $32.52 on March 15, 2023, a 12% decline. FOX's Class B stock has declined from a closing price of $34.22 on February 17, 2023 to a closing price of $29.83 on March 15, 2023, a 12% decline.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8811734)

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages LivePerson, Inc. Investors to Inquire About Securities Class Action Investigation – LPSN

NEW YORK, April 19, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of LivePerson, Inc. (NASDAQ: LPSN) resulting from allegations that LivePerson may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased LivePerson securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit–form/?case_id=13260 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

WHAT IS THIS ABOUT: On March 15, 2023, after the market closed, LivePerson issued a press release announcing its fourth quarter 2022 financial results, which included a net loss and revenue decline. LivePerson also revealed that its subsidiary, WildHealth, received a notice that Medicare was suspending reimbursement for services rendered under the Medicare demonstrate program (the "Program") in which certain non–core services would be provided and reimbursed by Medicare. Accordingly, LivePerson stated that given the "inherent uncertainty as to the timing and amount of further reimbursement for services rendered under the Program, the Company has elected to take a reserve for revenue associated with services delivered under the Program in the fourth quarter of 2022 for which payment has not yet been collected."

On this news, LivePerson's stock price fell $5.64, or 57% to close at $4.13 per share on March 16, 2023, damaging investors.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8811723)

TSE SHAREHOLDER ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Trinseo PLC Investors to Inquire About Securities Class Action Investigation – TSE

NEW YORK, April 19, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Trinseo PLC (NYSE: TSE) resulting from allegations that Trinseo may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Trinseo securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit–form/?case_id=13711 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

WHAT IS THIS ABOUT: On March 27, 2023, The Philadelphia Inquirer published an article entitled "Bristol plant that spilled chemicals into Philly's water supply had other mishaps over the last decade." The article reported "a chemical plant in Bristol that authorities said caused a toxic spill, threatening Philadelphia's drinking water, has a long history of mishaps "" including at least four recent contamination incidents." The article also stated "over the past decade, the U.S. Coast Guard twice before detected releases of acrylates [commonly used to produce glass–like acrylics] from the Bristol facility into the Delaware [River]. The EPA had separately flagged two other acrylate releases." The article further stated that "David Salas–de la Cruz, a Rutgers University associate professor of chemistry, worked at the Bristol plant during its Rohm and Haas days. He said the number of incidents over the past decade was unusual."

On this news, the price of Trinseo's stock fell $1.09, or 5%, to close at $19.62 per share on March 27, 2023.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8811633)

Le film Le Loup de Wall Street lancera l'offre NFT, propulsée par Aventus

LONDRES, 19 avr. 2023 (GLOBE NEWSWIRE) — Aventus, un fournisseur de solutions Web3 pour les entreprises, s'est associ aux dtenteurs des droits cinmatographiques du film Le loup de Wall Street et des producteurs et diteurs de films de renomme mondiale pour lancer l'Exprience du Loup de Wall Street : une srie de gouttes NFT qui serviront galement de cl pour dbloquer des volets plus vastes de l'exprience.

Avec un box–office mondial de prs de 400 millions de dollars, cinq nominations aux Oscars, dont le meilleur film, et une entre dans le livre Guinness World Records pour le plus grand nombre de jurons dans un film, l'impact du Loup de Wall Street sur la culture populaire reste inbranlable prs d'une dcennie aprs sa sortie, les memes du film continuant gnrer des millions d'utilisations.

L'exprience du Loup de Wall Street permettra aux fans du film et aux passionns du Web3 d'accder du contenu, des rcompenses et des expriences exclusives via une srie limite de gouttes NFT, y compris des scnes indites du tournage du film, du contenu dbloquer, des expriences et un accs limit un vnement sur invitation pour clbrer l'anniversaire du film.

Son lancement est prvu pour le deuxime trimestre 2023, avec des avantages supplmentaires pour les premiers participants de la communaut.

Les NFT seront crs par le rseau neutre en carbone Aventus, une couche 1 (parachaine) sur Polkadot, ce qui signifie que le projet tirera parti de tous les avantages de l'cosystme Polkadot, y compris l'volutivit, la vitesse, l'interoprabilit et la scurit accrues. Cela implique galement que les dtenteurs de NFT pourront tirer pleinement parti des avantages de l'interoprabilit sur plus de 50 blockchains, y compris Ethereum.

Alan Vey, fondateur et PDG d'Aventus, a dclar: Le Loup de Wall Street est l'un des films les plus emblmatiques non seulement de la culture populaire en gnral, mais aussi tout particulirement au sein de la communaut des blockchains. Nous sommes ravis de pouvoir prsenter ce film sur le Web3 et de faire partie d'un moment historique pour l'industrie, car la superproduction devient le dernier secteur tirer parti des avantages des NFT dans le renforcement et l'engagement de la communaut.

Gavin Wood, fondateur de Polkadot & Ethereum, a ajout: L'cosystme parachain de Polkadot vise aider les blockchains atteindre leurs objectifs en offrant une volutivit, une scurit et une interoprabilit amliores, et il est rjouissant de constater qu'Aventus a su tirer parti de ce partenariat pour mener bien ce projet vritablement novateur.

propos d'Aventus
Aventus fournit des solutions Web3 robustes, flexibles et encadres pour les entreprises souhaitant tirer parti des avantages de la blockchain, afin de prenniser leurs oprations, de gnrer de nouvelles sources de revenus et d'amliorer leur efficacit oprationnelle.

Avec plus de soixante–dix ans d'exprience en matire de Web3 et de direction d'entreprise, Aventus conoit des solutions optimises adaptes aux besoins spcifiques d'une entreprise pour favoriser la transformation et l'ducation par le Web3, et gre la solution, afin que les entreprises puissent se concentrer sur leur mission principale.
https ://www.aventus.io/

Demandes de renseignements des mdias :
aventus@thephagroup.com


GLOBENEWSWIRE (Distribution ID 1000804892)

O Lobo de Wall Street lançará uma oferta de NFT, promovida pela Aventus

LONDRES, April 19, 2023 (GLOBE NEWSWIRE) — A Aventus, fornecedora de solues Web3 para empresas, fez uma parceria com os detentores dos direitos cinematogrficos de O Lobo de Wall Street e produtores e editores de cinema lderes mundiais para criar The Wolf of Wall Street Experience: uma srie de lanamentos de NFT que tambm atuaro como uma chave para desbloquear partes mais amplas da experincia.

Com uma bilheteria mundial de quase US$ 400 milhes, cinco indicaes ao Oscar, incluindo Melhor Filme, e uma entrada no Guinness World Records para a maioria dos juramentos em um filme, o impacto de O Lobo de Wall Street na cultura popular permanece firme quase uma dcada aps seu lanamento, com memes do filme continuando a gerar milhes de usos.

The Wolf of Wall Street Experience dar aos fs do filme e aos entusiastas da Web3 acesso a contedo, recompensas e experincias exclusivas por meio de uma srie de lanamentos limitados de NFT, incluindo cenas nunca vistas da produo do filme, contedo desbloquevel, experincias e acesso limitado a um evento apenas para convidados para celebrar o aniversrio do filme.

O lanamento est programado para o segundo trimestre de 2023, com benefcios adicionais para os primeiros participantes da comunidade.

Os NFTs sero criados pela Rede Aventus, neutra em carbono, que uma camada 1 (parachain) na Polkadot "" o que significa que o projeto aproveitar todos os benefcios do ecossistema Polkadot, incluindo maior escalabilidade, velocidade, interoperabilidade e segurana. Isso tambm significa que os detentores de NFT podero aproveitar todos os benefcios da interoperabilidade em mais de 50 blockchains, incluindo o Ethereum.

Alan Vey, fundador e CEO da Aventus, comentou:”O Lobo de Wall Street um dos filmes mais icnicos no apenas da cultura popular de forma mais ampla, mas especificamente dentro da comunidade blockchain. Estamos entusiasmados por poder trazer este filme para a Web3 e por fazer parte de um momento histrico para a indstria, medida que o blockbuster se torna o setor mais recente a perceber os benefcios dos NFTs na construo e engajamento da comunidade”.

Gavin Wood, fundador da Polkadot & Ethereum, acrescentou:”O ecossistema de parachain da Polkadot visa ajudar os blockchains a atingir seus objetivos, oferecendo maior escalabilidade, segurana e interoperabilidade, e maravilhoso ver a Aventus alavancar esse suporte para viabilizar esse projeto verdadeiramente inovador”.

Sobre a Aventus
A Aventus fornece solues Web3 robustas, flexveis e gerenciadas para empresas que buscam aproveitar os benefcios do blockchain visando preparar suas operaes para o futuro, gerar novos fluxos de receita e melhorar a eficincia operacional.

Com uma experincia combinada de mais de sete dcadas na Web3 e liderana empresarial, a Aventus cria solues otimizadas adaptadas s necessidades exclusivas de uma empresa para permitir a transformao e a educao da Web3 e gerencia a soluo – para que as empresas possam se concentrar no que fazem de melhor.
https://www.aventus.io

Comunicao social:
aventus@thephagroup.com


GLOBENEWSWIRE (Distribution ID 1000804892)